Ann Kramer, CEO
Ann graduated from the University of Cambridge with a degree in Natural Sciences and joined ICI Agrochemicals. Over almost 20 years with ICI, Zeneca and Syngenta she gained experience across the business including in research, sales, business development and M&A, with roles in the UK, USA and Switzerland. She managed the development of genetically modified food business streams in fresh produce crops. Since 2006 she has worked in the SME sector in the UK as Head of Business development for Oxitec Ltd. (acquired by Intrexon in 2015), COO of Immunocore Ltd. and CEO of Biosyntha Ltd. She joined The Electrospinning Company as CEO in 2012.
Dr Rob McKean, Head of R&D
Rob holds a PhD from the University of Sheffield and gained post-doctoral experience working in world-class electrospinning laboratories at the University of Sheffield and at the Micro and Nanotechnology Centre based at the Rutherford Appleton Laboratory. His research activities focused on the development of 3D polymer scaffolds for a variety of regenerative medicine applications including full thickness skin reconstruction, degradable patches for cornea repair, orthopedic implant coatings, and nerve guide conduits. He joined TECL in 2010 as Head of Research and Development and is responsible for all R&D, Quality Management and regulatory aspects, product development, intellectual property protection, production and collaborations with industry and academia. Dr McKean is also the sole inventor of patented multi-well plate technology for 3D cell based assays that has received two awards for ‘Most Innovative New Technology’ by delegates of the ELRIG Drug Discovery conference.
Board of Directors
Drummond Paris, NED
Drummond has an impressive record of business achievements. After early experience in Pharmaceutical Sales, Sales Management , Marketing and Clinical Research, he was appointed to a number of increasingly senior management positions in the Pharmaceutical Industry with Sandoz and Novartis. More recently, in non-executive chairmanship roles, he lead the Board in supporting management to build an attractive medical technology business to guide an early stage, medical technology Company (Sirigen) towards a trade-sale exit where business was acquired by Becton Dickinson. He then assisted the start-up Pharma company (Karus Therapeutics) over a 7 year period in supporting the business to raise sufficient funding to permit the development of 2 unique classes of small molecule cancer therapies. He stepped down from this role in 2014 after the Company successfully received the second tranche of £20 million series B investment from a syndicate of 3 major life- science VCs. Drummond joined the Board in July 2016 and served as Chair until October 2018. He represents the interests of Angel shareholders.
Mark White, Observer
Mark is Investment Director and Investment Committee member of the Rainbow Seed Fund, an investor in The Electrospinning Company. He has over twenty years experience in investment with extensive periods in UK investment banking and emerging markets, including raising and managing a R100m fund in South Africa. Most recently, he led the transformation of NESTA’s investment operations, building it into the most active technology seed investor in the UK. He holds an MBA from London Business School.
Dr Kate Roynane, NED
Kate is Head of Innovation at the Science and Technology Facilities Council (STFC). The STFC established The Electrospinning Company in 2010 and have invested in the Company. During her PhD, she worked in the Sales and Marketing division of Andor, a Belfast-based startup before joining STFC as a research scientist. In 2008, Kate joined the Innovation team at STFC where she is responsible for the exploitation of the Council’s IP portfolio. She currently represents STFC on the board of a number of spin-out companies. Kate has a BSc and PhD in Chemistry from The Queen’s University, Belfast.
Dr Stewart White, Chairman
Stewart was previously CEO of two life science AIM-quoted companies including Collagen Solutions plc. Stewart is currently CEO of Novel Technologies Holdings Limited and Chairman of Mikota Ltd. Stewart has international executive experience in commercialisation, product development, GMP manufacturing of medical devices, advanced biologics and API’s in both SMEs and global pharmaceuticals. With specific experience in the use of biomaterials within medical devices and regenerative medicine, Stewart brings recent and direct knowledge of operating in companies which require to balance revenue generation with Intellectual Property development to underpin future growth and value accretion.
A Visiting Professor at the University of Glasgow in Technology Entrepreneurship, Stewart is a graduate of the University of Strathclyde and holds a First Class degree in Applied Microbiology, a Ph.D. in Fermentation Technology and Bioprocessing, and, an MBA.
Professor David Williams, OBE
David is Professor of Healthcare Engineering at Loughborough University. He has held senior leadership positions in academia and industry, working for much of his career at their interface and in healthcare since 1999. Responsibilities have included line, change and consortium management. David has published ~400 refereed journal and conference papers, has held >£40M of research grant income, successfully supervised >20 PhDs and founded two world class research groups. The last decade focussed on leadership of major research and research training initiatives in regenerative medicine (RM) and leading multi-disciplinary health research across the Loughborough campus. His early career was primarily in Cambridge University. Personal research addresses manufacturing and regulatory science of clinician-pulled cell based therapies and opportunities for engineers within defence medicine. Recent policy contributions include oral evidence to the House of Lords Select Committee in RM (2013) and membership of the Department of Health RM Expert Group (2014). He was made a Fellow of the Royal Academy of Engineering (FREng) in 2002 and an Officer of the Order of the British Empire (OBE) in 2014 for services to science and engineering.
Dr Lorenzo Moroni
Lorenzo received his Ph.D. in 2006 at University of Twente on 3D scaffolds for osteochondral regeneration, for which he was awarded the European doctorate award in Biomaterials and Tissue Engineering from the European Society of Biomaterials (ESB). In 2007, he worked at Johns Hopkins University as a post-doctoral fellow in the Elisseeff lab, focusing on hydrogels and stem cells. In 2008, he was appointed the R&D director of the Musculoskeletal Tissue Bank of Rizzoli Orthopedic Institute, where he investigated the use of stem cells from alternative sources for cell banking, and the development of novel bioactive scaffolds for skeletal regeneration. From 2009 till 2014, he joined again University of Twente, where he got tenured in the Tissue Regeneration department. Since 2014 he works at Maastricht University and in 2016 he became professor in biofabrication for regenerative medicine at the MERLN Institute for Technology-Inspired Regenerative Medicine. His research group interests aim at developing biofabrication technologies to generate libraries of 3D scaffolds able to control cell fate. In 2014, he received the prestigious Jean Leray award for outstanding young principal investigators from the ESB and the ERC starting grant. In 2016, he also received the prestigious Young Scientist Award for outstanding principal investigators from TERMIS.